AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
Stocks · News reference
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading